Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Anthem

PharmaDeviceNews Anthem

Anthem coverage of C2N Diagnostics’ PrecivityAD2 blood test could expand access to Alzheimer’s disease evaluation through blood-based biomarker testing. Representative image.

Medical Devices & Diagnostics

C2N Diagnostics gains Anthem coverage for PrecivityAD2 blood-based Alzheimer’s evaluation

by Pallavi Madhiraju
July 11, 2026
0 Comments

Anthem will cover C2N Diagnostics’ PrecivityAD2 from October 2026. Read what the move means for Alzheimer’s blood testing access.

Read More

Latest news and features

Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?
EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial
Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study
Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?
Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?
Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform
Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis
Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials
OD-001 ulcerative colitis study shows clinical response in 61% of higher-dose patients
Bezisterim Phase 2 results highlight potential new treatment approach for Parkinson’s disease symptoms
Rapport Therapeutics’ RAP-219 delivers statistically significant bipolar mania improvements in Phase 2 trial

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Viridian Therapeutics’ FDA-approved Lumvoa enters the thyroid eye disease market with a five-infusion treatment course, intensifying competition with Tepezza. Representative image.

Medical Devices & Diagnostics

FDA approves Genentech’s ENSPRYNG as first at-home treatment for thyroid eye disease

October 18, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Latest business and industry news

Moderna (MRNA) falls 18% despite melanoma win: Can an $81bn valuation hold?
Fractyl Health just hit a pivotal endpoint. Why is it cutting 45% of its workforce?
Stablepharma begins pivotal trial of fridge-free vaccine stable for 24 months at 30°C
Aptar’s most profitable business has a new leader. Can Virginie Maes restart margin expansion?
American Airlines loses $269m despite record $16.3bn revenue as fuel costs surge

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.